1. Home
  2. GNLX vs CVRX Comparison

GNLX vs CVRX Comparison

Compare GNLX & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$3.01

Market Cap

133.0M

Sector

Health Care

ML Signal

HOLD

Logo CVRx Inc.

CVRX

CVRx Inc.

HOLD

Current Price

$5.38

Market Cap

139.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNLX
CVRX
Founded
2001
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.0M
139.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
GNLX
CVRX
Price
$3.01
$5.38
Analyst Decision
Strong Buy
Buy
Analyst Count
4
4
Target Price
$17.25
$10.50
AVG Volume (30 Days)
145.4K
227.3K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
9.47
23.02
EPS
N/A
N/A
Revenue
$8,000.00
$56,651,000.00
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$17.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.45
52 Week Low
$2.29
$4.37
52 Week High
$8.54
$11.30

Technical Indicators

Market Signals
Indicator
GNLX
CVRX
Relative Strength Index (RSI) 43.80 44.79
Support Level $2.74 $4.59
Resistance Level $2.98 $5.96
Average True Range (ATR) 0.12 0.32
MACD -0.01 -0.01
Stochastic Oscillator 20.75 24.60

Price Performance

Historical Comparison
GNLX
CVRX

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

About CVRX CVRx Inc.

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Share on Social Networks: